MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$215,897K
Free Cash flow
$126,921K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from issuance of 2031 c...
Total revenues
Sale of marketable securities- a...
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Repurchase of the 2026 convertib...
Non-cash royalty revenue related...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenues
360,519
272,551
164,677
211,007
Cost of product, collaboration and license sales
10,932
19,679
186
12,441
Program spend
42,581
37,544
57,903
45,940
Employee costs
68,348
76,121
85,821
64,470
Manufacturing costs
6,232
9,085
21,806
11,047
Administrative costs
16,548
16,688
18,881
18,614
Occupancy costs
7,494
8,354
7,883
7,853
Total other segment items
124,888
107,889
107,162
34,746
Net income (loss) attributable to common stockholders
83,496
-2,809
-134,965
15,896
Depreciation and amortization
15,874
15,413
12,902
11,109
Non-cash operating lease expense
1,792
1,761
1,832
2,001
Non-cash royalty revenue related to sale of future royalties
71,105
46,835
79,408
64,061
Non-cash interest expense on liability related to sale of future royalties
65,309
65,699
65,853
49,976
Change in valuation of contingent consideration
-
-
0
0
Tangible asset impairment
-
-
500
419
Loss on sale of fixed assets
-
-
0
-30
Gain on lease modification
-
-
10,775
-
Unrealized (gain) loss on clearpoint equity investments
-
-
0
8,812
Tangible asset impairment and losses on transactions, net
0
-927
-
-
Realized loss on sale of clearpoint equity investment
-
-
-7,081
-
Inducement expense related to repurchase of 2026 convertible notes
3,386
-
-
-
Unrealized gain on marketable securities - equity investments
700
1,214
800
1,622
Disposal of asset
-
-
0
-163
Deferred income taxes
-
-10
1
-4
Amortization of discounts on investments, net
4,156
4,114
5,050
6,103
Amortization of debt issuance costs
384
305
313
305
Share-based compensation expense
23,291
23,421
18,518
19,426
Unrealized foreign currency transaction losses, net
-1,345
887
1,388
171
Inventory, net
15,860
-2,643
26,779
18,526
Prepaid expenses and other current assets
-8,364
-1,180
22,942
1,679
Trade and royalty receivables, net
19,728
40,390
-22,214
6,474
Deposits and other assets
-1,009
1,588
-1,137
-2,328
Accounts payable and accrued expenses
37,500
-68,713
108,082
-43,205
Other liabilities
-1,816
-2,309
9,101
-9,177
Deferred revenue
718
-1,522
300
-8,143
Payments on contingent consideration
-
-
0
0
Net cash provided by operating activities
129,113
-59,042
-34,273
-66,301
Purchases of fixed assets
2,192
1,197
2,374
3,445
Proceeds from sale of fixed assets
-
-
0
0
Purchases of marketable securities- available for sale
466,973
454,670
312,263
204,103
Purchases of marketable securities- equity investments
9,019
23,957
7,091
29,508
Sale of marketable securities- available for sale
332,966
376,359
359,545
177,200
Sale of marketable securities- equity investments
27,614
9,885
18,696
22,983
Sale of clearpoint equity investments
-
-
12,412
-
Acquisition of product rights and licenses
4,952
156
34,917
252,750
Net cash used in investing activities
-122,556
-93,736
34,008
-289,623
Proceeds from exercise of options
13,234
6,403
59,387
16,830
Proceeds from employee stock purchase plan
3,163
-
3,117
0
Repurchase of the 2026 convertible notes
327,890
-
-
-
Cash consideration received from a&r royalty purchase agreement
-
-
240,000
-
Conversion of the 2026 convertible notes
12,879
-
-
-
Payments on contingent consideration obligation
-
-
0
0
Debt issuance costs related to 2031 convertible notes
13,750
-
-
-
Payment of finance lease principal
-
-
0
1,611
Proceeds from issuance of 2031 convertible notes
550,000
-
-
-
Net cash provided by financing activities
211,878
6,403
302,504
15,219
Effect of exchange rate changes on cash
-2,538
-1,524
9,795
-6,064
Net increase in cash and cash equivalents
215,897
-147,899
312,034
-346,769
Cash and cash equivalents, and restricted cash beginning of period
686,300
686,300
-
795,316
Cash and cash equivalents, and restricted cash end of period
1,066,332
850,435
-
686,300
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Total revenues
$360,519K
(-73.39%↓ Y/Y)
Proceeds from issuance of
2031 convertible...
$550,000K
Net income (loss)
attributable to common...
$83,496K
(-89.59%↓ Y/Y)
Non-cash interest
expense on liability...
$65,309K
(-34.25%↓ Y/Y)
Proceeds from exercise of
options
$13,234K
(-21.62%↓ Y/Y)
Proceeds from employee
stock purchase plan
$3,163K
(11.89%↑ Y/Y)
Canceled cashflow
$277,023K
Accounts payable and
accrued expenses
$37,500K
(446.33%↑ Y/Y)
Share-based compensation
expense
$23,291K
(-36.37%↓ Y/Y)
Depreciation and
amortization
$15,874K
(7.23%↑ Y/Y)
Prepaid expenses and
other current assets
-$8,364K
(-168.57%↓ Y/Y)
Inducement expense related
to repurchase of...
$3,386K
Non-cash operating lease
expense
$1,792K
(-50.69%↓ Y/Y)
Unrealized foreign
currency transaction...
-$1,345K
(72.77%↑ Y/Y)
Deposits and other assets
-$1,009K
(-222.01%↓ Y/Y)
Deferred revenue
$718K
(-81.33%↓ Y/Y)
Amortization of debt issuance
costs
$384K
(-36.11%↓ Y/Y)
Net cash provided by
financing activities
$211,878K
(1484.61%↑ Y/Y)
Net cash provided by
operating activities
$129,113K
(-84.09%↓ Y/Y)
Canceled cashflow
$354,519K
Canceled cashflow
$113,365K
Total other segment
items
$124,888K
(-43.67%↓ Y/Y)
Employee costs
$68,348K
(-48.72%↓ Y/Y)
Program spend
$42,581K
(-56.49%↓ Y/Y)
Administrative costs
$16,548K
(-54.43%↓ Y/Y)
Cost of product,
collaboration and license...
$10,932K
(-30.81%↓ Y/Y)
Occupancy costs
$7,494K
(-45.79%↓ Y/Y)
Manufacturing costs
$6,232K
(-81.92%↓ Y/Y)
Net increase in cash
and cash...
$215,897K
(-9.19%↓ Y/Y)
Canceled cashflow
$125,094K
Repurchase of the 2026
convertible notes
$327,890K
Debt issuance costs
related to 2031...
$13,750K
Conversion of the 2026
convertible notes
$12,879K
Non-cash royalty revenue
related to sale of future...
$71,105K
(-16.44%↓ Y/Y)
Trade and royalty
receivables, net
$19,728K
(-23.80%↓ Y/Y)
Inventory, net
$15,860K
(84.61%↑ Y/Y)
Amortization of discounts on
investments, net
$4,156K
(-39.50%↓ Y/Y)
Other liabilities
-$1,816K
(89.52%↑ Y/Y)
Unrealized gain on
marketable securities -...
$700K
(-54.49%↓ Y/Y)
Sale of marketable
securities- available for...
$332,966K
(34.72%↑ Y/Y)
Sale of marketable
securities- equity...
$27,614K
(61.21%↑ Y/Y)
Net cash used in
investing activities
-$122,556K
(79.79%↑ Y/Y)
Effect of exchange rate
changes on cash
-$2,538K
(-113.37%↓ Y/Y)
Canceled cashflow
$360,580K
Purchases of marketable
securities- available for...
$466,973K
(-44.88%↓ Y/Y)
Purchases of marketable
securities- equity...
$9,019K
(-47.04%↓ Y/Y)
Acquisition of product
rights and licenses
$4,952K
(42.09%↑ Y/Y)
Purchases of fixed assets
$2,192K
(-27.92%↓ Y/Y)
Buy us a coffee
PTC THERAPEUTICS, INC. (PTCT)
PTC THERAPEUTICS, INC. (PTCT)